-
A cost analysis of upfront DPYD genotype–guided dose individualisation in fluoropyrimidine-based anticancer therapy
Henricks, L. M., Lunenburg, C. A. T. C., de Man, F. M., Meulendijks, D., Frederix, G. W. J., Kienhuis, E., Creemers, G.-J., Baars, A., Dezentjé, V. O., Imholz, A. L. T., Jeurissen, F. J. F., Portielje, J. E. A., Jansen, R. L. H., Hamberg, P., ten Tije, A. J., Droogendijk, H. J., Koopman, M., Nieboer, P., van de Poel, M. H. W. & Mandigers, C. M. P. W. & 11 others, , 2019, In: European journal of cancer (Oxford, England. 107, p. 60-67Research output: Contribution to journal › Article* › Academic › peer-review
-
Capecitabine-based treatment of a patient with a novel DPYD genotype and complete dihydropyrimidine dehydrogenase deficiency
Henricks, L. M., Siemerink, E. J. M., Rosing, H., Meijer, J., Goorden, S. M. I., Polstra, A. M., Zoetekouw, L., Cats, A., Schellens, J. H. M. & van Kuilenburg, A. B. P., 2018, In: International journal of cancer. Journal international du cancer. 142, 2, p. 424-430Research output: Contribution to journal › Article* › Academic › peer-review
-
DPYD genotype-guided dose individualisation of fluoropyrimidine therapy in patients with cancer: a prospective safety analysis
Henricks, L. M., Lunenburg, C. A. T. C., de Man, F. M., Meulendijks, D., Frederix, G. W. J., Kienhuis, E., Creemers, G.-J., Baars, A., Dezentjé, V. O., Imholz, A. L. T., Jeurissen, F. J. F., Portielje, J. E. A., Jansen, R. L. H., Hamberg, P., ten Tije, A. J., Droogendijk, H. J., Koopman, M., Nieboer, P., van de Poel, M. H. W. & Mandigers, C. M. P. W. & 11 others, , 2018, In: lancet oncology. 19, 11, p. 1459-1467Research output: Contribution to journal › Article* › Academic › peer-review
- All publications
